* Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected
to show a
rise in quarterly revenue when it reports results on November
13 for the period ending September 30 2024
* The New York City-based company is expected to report a
45.6% increase in revenue to $1.14 million from $783 thousand a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Lucid Diagnostics Inc is
for a
loss of 22 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Lucid
Diagnostics
Inc is 3.00, above its last closing price of $1.04.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.22 -0.22 -0.23 Missed -4.5
Mar. 31 2024 -0.26 -0.40 -49.3
Dec. 31 2023 -0.27 -0.26 -0.25 Beat 3
Sep. 30 2023 -0.27 -0.27 -0.34 Missed -24.8
Jan. -0.32 -0.32 -0.23 Beat 28.3
1 0001
Mar. 31 2023 -0.34 -0.35 -0.40 Missed -14.7
Dec. 31 2022 -0.37 -0.38 -0.23 Beat 39.3
Sep. 30 2022 -0.42 -0.40 -0.39 Beat 1.7
This summary was machine generated November 11 at 15:34 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)